Phathom Pharmaceuticals (PHAT) Net Cash Flow (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Net Cash Flow data on file, last reported at $50.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 159.96% year-over-year to $50.9 million in Q1 2026; TTM through Mar 2026 was -$31.4 million, a 71.42% increase from a year earlier, with the FY2025 full-year figure at -$167.3 million, down 98.85% from the prior year.
• Net Cash Flow for Q1 2026 stood at $50.9 million, up from -$5.2 million in the prior quarter.
• Over the last five years, Net Cash Flow for PHAT reached as high as $167.7 million in Q4 2023 and fell as low as -$84.9 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$5.6 million across 5 years, with a median of -$26.1 million in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 556.3% in 2023 and fell as far as 211.16% in 2023.
• Year by year, Net Cash Flow stood at -$41.5 million in 2022, then jumped by 504.61% to $167.7 million in 2023, then sank by 122.31% to -$37.4 million in 2024, then soared by 86.14% to -$5.2 million in 2025, then surged by 1082.3% to $50.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $50.9 million in Q1 2026, -$5.2 million in Q4 2025, and -$14.4 million in Q3 2025.